A small study conducted in China suggests pregnant women with idiopathic pulmonary arterial hypertension (iPAH) are at higher risk of maternal mortality compared with women with certain other types of pulmonary hypertension (PH).
Among pregnant women with pulmonary hypertension (PH), maternal mortality was higher for those who had idiopathic pulmonary arterial hypertension (iPAH) vs women with PAH related to congenital heart disease (CHD-PAH) or other diseases (oPAH) or PH related to left heart disease (LHD-PH).
In general, researchers found significant differences in maternal-fetal outcomes among women with iPAH, CHD-PAH, oPAH, and LHD-PH.
“With the application of targeted drug therapy in recent years, the prognosis of PAH patients has been significantly improved,” they said. “However, some studies have shown that the mortality rate of patients with PH is still as high as 13% to 18% in the first year.”
This retrospective study, published in BMC Pregnancy and Childbirth, included clinical data of 154 pregnant women with PH admitted to the Third Affiliated Hospital of Guangzhou Medical University in China between January 2011 and December 2020.
The median (SD) age of these women was 30.9 (5.1) years, ranging from 21 to 46 years. Of this group, 6 (3.9%) had iPAH, 41 (26.6%) had CHD-PAH, 45 (29.2%) had oPAH, and 62 (40.3%) had LHD-PH. Systolic pulmonary artery pressure (sPAP) was 36 to 49 mm Hg in 53.2% of patients, 50 to 69 mm Hg in 22.1% of patients, and ≥ 70 mm Hg in 24.7% of patients.
The median gestational week during hospitalization was 35.5 weeks, ranging between 6 and 41 weeks for the whole group. Fifty-four women (35.1%) were admitted to the intensive care unit (ICU), with women in the iPAH group having the highest ICU admission rate at 83.3%, followed by the LHD-PH group (37.1%), the CHD-PAH group (36.6%), and the oPAH group (24.4%). The authors reported this difference as statistically significant (P < .05).
Additionally, 108 women (70.1%) underwent caesarean section, and the incidence of heart failure during pregnancy was 14.9%.
Pregnant women in the study also experienced the following:
Five pregnant women died within a week after delivery, and the 1-week postpartum mortality rate among pregnant women with PH overall was 3.2%. Although pregnant women with iPAH had the highest mortality rate of 50%, it is important to note this reflects 3 of 6 women, a very small sample size and a much smaller group compared with the other 3 groups included in the study.
“This study was a single-centre retrospective investigation conducted in China, with a limited sample of the study populations, and there may be bias in the population representation,” the authors noted. “Second, since our study population consisted of pregnant women, cardiac colour Doppler ultrasonography, but not heart catheterization, was used as a diagnostic tool. This is a common limitation of similar studies.”
Based on this study’s findings, which warrant further research with larger sample sizes, the authors suggested individuals with iPAH should try to avoid pregnancy. For those who are at high risk but want to carry out their pregnancy, they recommend consultation with a doctor as soon as possible and standardized treatment.
“At the same time, we suggest that comprehensive hospitals should establish multidisciplinary assistance teams, including obstetrics, cardiovascular medicine, critical medicine, anaesthesiology, and neonatology specialists,” the authors said. “Clinicians must balance the pros and cons of maternal and fetal outcomes and choose the most appropriate treatment plan to improve maternal and fetal pregnancy outcomes.”
Reference
Lv C, Huang Y, Liao G, Wu L, Chen D, Gao Y. Pregnancy outcomes in women with pulmonary hypertension: a retrospective study in China. BMC Pregnancy Childbirth. 2023;23(1):16. doi:10.1186/s12884-023-05353-7
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Poor Sleep Quality Associated With Pulmonary Arterial Hypertension
November 14th 2024Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant predictor of sleep quality, independent of disease severity, according to this study.
Read More
Refinements to European Strategy Can Improve PAH-CHD Stratification
November 6th 2024When patients were re-classified based on the adjusted thresholds of N-terminal pro-brain natriuretic peptide and 6-minute walk distance and the inclusion of TAPSE rather than right atria area, classification of patients improved significantly.
Read More
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More